Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans
- PMID: 19491851
- DOI: 10.1038/ajg.2009.133
Novel removable internally fully covered self-expanding metal esophageal stent: feasibility, technique of removal, and tissue response in humans
Abstract
Objectives: Internally fully covered self-expandable metal stents (FCSEMSs) have recently become available offering the possibility of removal. However, to our knowledge, the feasibility, techniques for endoscopic removal, and tissue reaction to FCSEMS have not been reported in humans. Our aims are (1) to report reasons for and success of FCSEMS removal in consecutive patients, (2) to describe methods of esophageal stent retrieval, and (3) to describe stent reactions induced by FCSEMS in humans.
Methods: Removable FCSEMSs (ALIMAXX-E, Alveolus Inc., Charlotte, NC) were placed in consecutive patients requiring palliation of dysphagia symptoms with locally advanced esophageal or gastro-esophageal junction cancers, refractory benign esophageal strictures, postoperative mediastinal leaks, or tracheoesophageal fistulas. Dysphagia scores were assessed at 1, 3, and 6 months. Esophagogram and endoscopy follow-up were performed routinely at 1 month or to assess new symptoms.
Results: A total of 36 stents were placed in 31 patients over 16 months (mean age 62.8 years, 61% white, 58% male). Indications included the following: malignant strictures (n=17), refractory benign strictures (n=7), tracheoesophageal fistulas (n=8), postoperative mediastinal leaks (n=2), and iatrogenic perforations (n=2). Dysphagia scores improved (decreased) significantly at 1 (mean difference 2.09; 95% confidence interval (CI) 1.65-2.52, P=0.0001), 3 (mean difference 2.1; 95% CI 1.57-2.62, P=0.0001), and 6 months (mean difference of 2; 95% CI 1.28-2.73, P<0.0001). Clinical success rates for various indications were: malignant strictures 88%, refractory benign strictures 29%, tracheoesophageal fistula 88%, postoperative mediastinal leaks 100%, and iatrogenic perforations 50%. Sixty one percent (n=22) of the stents were removed (removal was successful in 100% of cases attempted). Twenty three percent (n=5 stents in four patients) were removed due to chest pain or abdominal pain. The stents satisfied their purposes in all of these four patients. The remainder were removed on schedule or had satisfied their purpose and/or migrated. Fifty percent of removed stents had ulcers (median size=2 cm) at the distal edge of the stent, whereas 23% had ulcers at the proximal edge of the stent. Pseudo-polyps formed at either the proximal or distal edge of the stent in four patients. Tissue reaction was severe in only two patients. Stents were embedded in four cases but were easily lifted from tissue. Our preferred method of retrieval was the double-channel therapeutic endoscope with two rat-tooth forceps or rat-tooth forceps with a snare.
Conclusions: FCSEMSs palliate dysphagia from both benign and malignant conditions and seal postoperative tracheoesophageal fistulas and mediastinal leaks. Tissue reaction to the stents was common but remained clinically insignificant in the majority of patients. Close follow-up of patients with FCSEMS is required and repeat endoscopy with stent retrieval might be necessary with the development of new symptoms or complications from the stent.
Similar articles
-
Self-expandable metal stents for the treatment of benign upper GI leaks and perforations.Gastrointest Endosc. 2011 May;73(5):890-9. doi: 10.1016/j.gie.2010.12.019. Gastrointest Endosc. 2011. PMID: 21521563
-
A pilot study of fully covered self-expandable metal stents prior to neoadjuvant therapy for locally advanced esophageal cancer.Dis Esophagus. 2010 May;23(4):309-15. doi: 10.1111/j.1442-2050.2009.01011.x. Epub 2009 Sep 24. Dis Esophagus. 2010. PMID: 19788439
-
A new fully covered metal stent for the treatment of benign and malignant dysphagia: a prospective follow-up study.Gastrointest Endosc. 2012 Apr;75(4):712-8. doi: 10.1016/j.gie.2011.11.036. Epub 2012 Jan 28. Gastrointest Endosc. 2012. PMID: 22284093
-
Advances in esophageal stenting: the evolution of fully covered stents for malignant and benign disease.Adv Ther. 2010 Jul;27(7):413-25. doi: 10.1007/s12325-010-0042-5. Epub 2010 Jun 28. Adv Ther. 2010. PMID: 20586003 Review.
-
Palliative treatment of malignant esophagorespiratory fistulas with Gianturco-Z stents. A prospective clinical trial and review of the literature on covered metal stents.Am J Gastroenterol. 1998 Apr;93(4):532-5. doi: 10.1111/j.1572-0241.1998.160_b.x. Am J Gastroenterol. 1998. PMID: 9576443 Review.
Cited by
-
Treatment of refractory post-esophagectomy anastomotic esophageal strictures using temporary fully covered esophageal metal stenting compared to repeated bougie dilation: results of a randomized controlled trial.Endosc Int Open. 2019 Feb;7(2):E178-E185. doi: 10.1055/a-0777-1856. Epub 2019 Jan 18. Endosc Int Open. 2019. PMID: 30705950 Free PMC article.
-
Removable, fully covered, self-expandable metal stents for the treatment of refractory benign esophagogastric anastomotic strictures.Dysphagia. 2012 Jun;27(2):260-4. doi: 10.1007/s00455-011-9361-1. Epub 2011 Aug 9. Dysphagia. 2012. PMID: 21826422
-
Small caliber covered self-expanding metal stents in the management of malignant dysphagia.J Gastrointest Oncol. 2016 Jun;7(3):411-9. doi: 10.21037/jgo.2015.12.03. J Gastrointest Oncol. 2016. PMID: 27284474 Free PMC article.
-
Fully covered removable nitinol self-expandable metal stents (SEMS) in malignant strictures of the esophagus: a multicenter analysis.Surg Endosc. 2012 Jun;26(6):1664-9. doi: 10.1007/s00464-011-2089-z. Epub 2011 Dec 17. Surg Endosc. 2012. PMID: 22179474
-
Electrocautery therapy combined with oral steroid administration for refractory corrosive esophageal stenosis prevents restenosis.Esophagus. 2013;10(4):230-234. doi: 10.1007/s10388-013-0375-7. Epub 2013 Apr 20. Esophagus. 2013. PMID: 24348280 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical